KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: A cohort study
Stanculeanu, D. L.
Kalofonos, H. P.
Google Scholar check
MetadataShow full item record
Objectives: Treatment decision-making in colorectal cancer is often guided by tumour tissue molecular analysis. The aim of this study was the development and validation of a high-resolution melting (HRM) method for the detection of KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer and determination of the frequency of these mutations in the respective populations. Setting: Diagnostic molecular laboratory located in Athens, Greece. Participants: 2425 patients with colorectal cancer participated in the study. Primary and secondary outcome measures: 2071 patients with colorectal cancer (1699 of Greek and 372 of Romanian origin) were analysed for KRAS exon 2 mutations. In addition, 354 tumours from consecutive patients (196 Greek and 161 Romanian) were subjected to full KRAS (exons 2, 3 and 4), NRAS (exons 2, 3 and 4) and BRAF (exon 15) analysis. KRAS, NRAS and BRAF mutation detection was performed by a newly designed HRM analysis protocol, followed by Sanger sequencing. Results: KRAS exon 2 mutations (codons 12/13) were detected in 702 of the 1699 Greek patients with colorectal carcinoma analysed (41.3%) and in 39.2% (146/372) of the Romanian patients. Among the 354 patients who were subjected to full KRAS, NRAS and BRAF analysis, 40.96% had KRAS exon 2 mutations (codons 12/13). Among the KRAS exon 2 wild-type patients 15.31% harboured additional RAS mutations and 12.44% BRAF mutations. The newly designed HRM method used showed a higher sensitivity compared with the sequencing method. Conclusions: The HRM method developed was shown to be a reliable method for KRAS, NRAS and BRAF mutation detection. Furthermore, no difference in the mutation frequency of KRAS, NRAS and BRAF was observed between Greek and Romanian patients with colorectal cancer.
Showing items related by title, author, creator and subject.
Prognostic significance of WNT and hedgehog pathway activation markers in cancer of unknown primary Fotopoulos, George; Goussia, Anna; Bareta, E.; Koumpis, E.; Chrisafi, S.; Bobos, M.; Malamou-Mitsi, Vassiliki D.; Fountzilas, George; Pavlidis, Nicholas; Pentheroudakis, George (2015)Background: Cancer of unknown primary (CUP) possesses distinct biology and peculiar natural history, in which the roles of the winged and hedgehog signalling pathways are unclear. Materials and methods: We constructed ...
High levels of topoisomerase IIα protein expression in diffuse large B-cell lymphoma are associated with high proliferation, germinal center immunophenotype, and response to treatment Pentheroudakis, George; Goussia, Anna; Voulgaris, E.; Nikolaides, C.; Ioannidou, E.; Papoudou-Bai, A.; Grepi, K.; Kanavaros, P.; Pavlidis, Nicholas; Bai, M. C. (2010)Gene copy number and protein expression of topoisomerase IIα were correlated to benefit from anthracyclines in various tumors. A retrospective series of 69 patients with DLBCL managed with CHOP chemotherapy were studied ...
p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: A ten-year follow-up study Stefanou, D. G.; Nonni, A. V.; Agnantis, Niki J.; Athanasiadou, S. E.; Briassoulis, E. Ch; Pavlidis, Nicholas (1998)The aim of this study was the evaluation of p53/MDM-2 protein overexpression in different subtypes of human sarcomas, and their correlation with proliferative activity and patient outcome. We selected 40 cases of human ...